Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers.
Artios has raised €258M across 3 funding rounds from 24 investors, most recently a Series D+ round in Nov 2025. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2025-11-17 | Series D+ | €99M | Andera Partners,Avidity Partners,EQT Life Sciences,Invus,IP Group PLC,Janus Henderson Investors+9 more | View deal → |
| 2021-07-27 | Series C | €130M | Avidity Partners,CaaS Capital Management,Deep Track Capital,Invus,Omega Funds,Piper Heartland Healthcare Capital+6 more | View deal → |
| 2016-09-01 | Series A | €29M | Abbvie Biotech Ventures,Imperial Innovations Limited,SV Life Sciences | View deal → |
